---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-005113"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2025-04-22T23:59:59+00:00"
generated_at: "2026-05-23T09:20:22.891277+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MetaVia reports dose-dependent weight loss and no CV effects in Phase 1 MAD study of DA-1726

## Summary
- Clear dose-dependent body weight reduction from 8 mg to 32 mg; BMI change significantly greater vs placebo.
- No drug-induced heart rate or QTcF increases up to 32 mg at 4 weeks; mean HR decreased in most cohorts.
- Previously reported: max weight loss -6.3% and mean -4.3% at Day 26 for 32 mg; fasted glucose lowered -18 mg/dL.
- Additional cohorts to determine maximum tolerated dose; 32 mg likely starting dose for future trials.
- All pre-funded warrants exercised for 1,430,000 shares post-announcement; no warrants outstanding.

## SEC filing metadata
- accession: 0001558370-25-005113
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2025-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837025005113/0001558370-25-005113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837025005113/mtva-20250422x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-005113
- JSON: https://secwatch.observer/filing/0001558370-25-005113.json
- Plain text: https://secwatch.observer/filing/0001558370-25-005113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.